Department of Cancer Biology

📣 Check out this interview with Prof. Magdalena Król titled “Research grants are easier to get abroad than in Poland” where she shares her firsthand experience with grant applications and financing projects for innovative medical treatments. Explore the challenges faced in Poland and the promising opportunities offered by organizations like the European Innovation Council. Don’t miss this thought-provoking interview that sheds light on the research funding landscape.

Read it here: https://edukacja.rp.pl/uczelnie-wyzsze/art38136581-prof-krol-granty-na-badania-naukowe-latwiej-dostac-za-granica-niz-w-polsce 🌍🔬

📢 Exciting News! Bartłomiej Taciak and Maciej Białasek, who both develop our cancer therapy based on MDCs, are attending the ISCT, International Society for Cell & Gene Therapy 2023 Conference! 🌍🧬

📌 ISCT 2023 Conference
📆 May 30th – June 3rd, 2023
🗺 Palais des Congrès de Paris
💻 https://www.isctglobal.org/isct2023/home

Join our researchers during the Poster Session and watch them presenting a poster titled “Macrophage-drug conjugate as a cell-based therapy for glioblastoma” to explore the future of cell and gene therapy!

👋 Join us at #SwissBiotechDay2023 to learn about our breakthrough macrophage-based immunotherapy for the treatment of solid tumors. Our presentation, titled “Breakthrough Macrophage Based Immunotherapy For Treatment Of Solid Tumors,” will be held on ⌚ April 24th at 16:15 – 16:30 in Room Rio, floor 2. Prof. Magdalena Król, Head of Department, will be the speaker.

As a clinical stage biotech company, Department of Cancer Biology is leading the way in the development of Macrophage Drug Conjugates (MDCs) – a new class of therapy for solid tumors. Using allogeneic macrophages conjugated with therapeutic medications, we’re focusing on the treatment of glioblastoma, ovarian, and pancreatic cancer. Our preclinical results show the elimination of tumors or significant tumor shrinkage, and we’re preparing to progress our technology to the first in human clinical trials.

Visit our website, www.cellis.eu, to learn more about our company profile and stay tuned for more updates from Swiss Biotech Day 2023!

Mark your calendars! Prof. Magdalena Król, Head of the Department, will be participating in Swiss Biotech Day 2023, held on April 24-25 at the Congress Center Basel, Switzerland. Their expertise and insights will undoubtedly make a valuable contribution to the discussions and conversations taking place.

Register for the event at https://swissbiotechday.ch/

We are happy to announce that our Head of the Department, Prof. Magdalena Król, has been invited to join the jury of an upcoming industry event #CEBioForum2023. As a leading expert in her field and a distinguished thought leader, her insights and expertise will help ensure that the winning solutions truly represent the best in the field.

See you on April 14th at #CEBioForum2023!

We are pleased to share that Prof. Magdalena Król, Head of the Department, has been awarded with the MACOV Transition Grant funded by the European Innovation Council (EIC)! The project MACOV aims to develop an innovative, allogeneic, off-the-shelf macrophage-based therapy for platinum-resistant ovarian cancer. This is a ground-breaking, first in class therapy that shows very high efficacy in multiple solid tumors of unmet medical need.

Read more here about this achievement!

We are thrilled to announce that our groundbreaking project, “Entrapment of hypoxic cancer by macrophages loaded with HAP,” has been selected as one of the top 25 innovations in Poland by the prestigious “My Company” magazine! The interview with Prof. Magdalena Król, where she discusses the project and its implications, can be found on the “My Company” website at the following link: Link to the interview with Prof. Magdalena Król. For more details on the top 25 innovators in Poland, including our project’s feature, we encourage you to read the full article available at: Link to the whole article. Stay tuned for more updates on our project as we continue to strive for excellence and contribute to the betterment of healthcare.